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                                  5          Summary 
 
 
 
1. BRIEF SUMMARY 
Background: Cardiac troponin and the electrocardiogram (ECG) are essential diagnostic tools in 
acute coronary syndrome. They are also important prognostic markers. Cardiac troponin reflects 
myocardial necrosis. Following reperfusion therapy for ST-elevation myocardial infarction 
(STEMI), ECG-derived measures of ST-segment recovery (STR) reflect tissue perfusion and are 
associated with clinical outcome. 
Aims: In a population of STEMI patients receiving primary percutaneous coronary intervention 
(pPCI), to study the association of cardiac troponin I (TnI) with infarct size (IS), left-ventricular 
(LV) function and volumes and microvascular obstruction (MVO); and to study the association 
of 3 measures of STR with IS and LV function. 
Methods: Post hoc analyses of the 227 patients enrolled in the overall negative FIRE (Efficacy 
of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. cTnI sampled at 24 and 48 
hours. STR calculated immediately following pPCI and at 90 minutes. The outcome measures 
(IS, MVO and LV function and volumes) were obtained by (late gadolinium enhanced) cardiac 
magnetic resonance (CMR) at 5-7 days and 4 months following the index event.  
Results: cTnI was significantly correlated with IS, LV ejection fraction (LVEF) and LV volumes 
at both 5-7 days and 4 months. The associations between cTnI and these outcome measures at 4 
months remained after adjustment for the early CMR evaluation. cTnI was associated with MVO 
independent of IS. All 3 STR algorithms were significantly associated with IS and LVEF at 4 
months. The simple metric of worst-lead residual ST-segment deviation evaluated at 90 minutes 
post-intervention was comparable to the more complex STR algorithms. 
Interpretation and conclusion: Both measurement of cTnI and calculation of STR provide 
useful information on IS and LV function and remodeling in STEMI patients treated with pPCI, 
and may allow for early and simple risk stratification of this patient population. The clinical 
utility of these findings for prognostic assessment awaits further prospective studies.  
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                                                             13                                                               Introduction                     
 
 
5. INTRODUCTION 
5.1 A Short History of Acute Myocardial Infarction 
Coronary artery disease is the leading cause of death worldwide (1). The global burden of 
cardiovascular disease is expected to increase in the coming years, as falling mortality rates from 
coronary artery disease in the Western world (2, 3) are more than offset by the continuing 
epidemiological transition in developing countries away from nutritional deficiencies and 
infectious disease towards chronic and degenerative pathologies, cardiovascular disease being the 
most prominent (4-6).  
Acute MI is a serious and potentially lethal manifestation of coronary artery disease, 
afflicting more than 7 million people worldwide each year (7). James Herrick established MI as a 
distinct clinical entity in 1912 and also installed the mainstay management strategy - which 
prevailed for the next 50 years - in stressing the importance of “absolute bed rest” (8). Thanks to 
a remarkable scientific journey throughout the last 60 years – spanning epidemiology, basic 
science, and clinical trials – such long-held beliefs are now considered obsolete; and a 
comprehensive, continually evolving evidence base has been generated, from which 
contemporary preventive and therapeutic strategies have been developed.  
Beginning in the late 1940s, prospective studies were designed to define lifestyle, 
environmental and other factors contributing to the incidence of MI (9-12). In the 1960s, 
designated coronary care units were established in many hospitals to monitor AMI patients and 
ensure prompt resuscitation in the event of life-threatening arrhythmias (13); a development 
called the “single most important advance in the treatment of acute MI” (14). These significant 
progressions were then augmented by basic science studies elucidating many of the key 
underlying mechanisms of AMI, which paved the way for landmark clinical trials spanning from 
acute interventions such as reperfusion therapy to long-term pharmacological therapies that are 
now cornerstones in the management of AMI patients (15-22). The combined impact of these 
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preventive and therapeutic measures has resulted in large reductions in mortality following AMI 
in the developed world (23).  
In STEMI, the last innovation to provide clear-cut incremental benefit has been the 
introduction of pPCI. When delivered in a timely fashion pPCI reduces early death, re-infarction 
and stroke compared to pharmacological reperfusion by fibrinolysis (24). Further therapeutic 
innovations and effective preventive strategies are still being pursued (25, 26). Among these are 
efforts to protect the ischemic myocardium against reperfusion injury. Reperfusion injury refers 
to tissue damage occurring as a consequence of blood supply being reestablished after a period of 
ischemia (27). Mitigation of reperfusion injury has been demonstrated in animal models, but 
proved difficult to replicate in clinical studies (28). Several approaches have been tested, but 
none have yet demonstrated efficacy in pivotal clinical trials (29, 30). The FIRE (Efficacy of 
FX06 in the Prevention of Myocardial Reperfusion Injury) trial, from which database this thesis 
is based, also failed to replicate experimental findings in a clinical setting (31, 32). The concept 
of post-conditioning has emerged as one of the most promising strategies to confer 
cardioprotection in the setting of reperfusion (33, 34). It is currently being evaluated in multiple 
randomized trials. So far, results have been encouraging (35, 36), but benefits may be restricted 
to patients with large infarctions (37). 
Despite the significant improvements in prognosis, a gradient of risk still exist following 
AMI, and risk stratification remains crucial to allocate resources efficiently, optimize patient 
outcomes and limit adverse events. Particularly, early identification of high-risk patients with 
extensive myocardial injury is important to ensure appropriate administration of 
pharmacotherapies and prophylactic interventions (22, 38, 39).  
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5.2 Brief overview of the thesis 
The studies upon which this thesis is built aimed to gain specific insight into the prognostic 
applications of two well-established diagnostic and risk stratification tools for evaluation of 
STEMI patients: Cardiac troponin measurements and the ECG.  The methodological approach is 
simple: Essentially, measurements of cTnI levels and assessment of ST-segment recovery 
following pPCI are analyzed in relation to the extent and degree of myocardial necrosis and 
cardiac function and volumes, all determined by CMR. The analyses are based on investigations 
performed on a population of STEMI patients treated with pPCI within 6 hours from onset of 
symptoms. The study population participated in a randomized, placebo-controlled trial (FIRE) 
designed to characterize the safety and potential cardioprotective properties of a novel compound 
called FX06 in the setting of reperfusion therapy for STEMI. The FIRE trial was negative 
regarding the primary endpoint of CMR determined infarct size at 5-7 days.  
The first section will place the subject in context. An overview of the cardiac troponins and 
their contemporary applications in the management of AMI will be followed by an introduction 
to the concept and history of estimating myocardial necrosis by blood-borne biomarkers. Last, 
the use of ST-segment analysis for assessment of reperfusion status and prognosis will be 
summarized. To facilitate interpretation of the rationale of my own investigations, the 
“knowledge gap” that this project sought to fill will be highlighted in the relevant sections, before 
the specific aims of this thesis will be articulated in the next chapter.   
 The subsequent parts will cover the methods used and the findings of our investigations. A 
discussion of the main results of each study will be followed by a consideration of the 
methodological approach, before the findings of the project as a whole are interpreted in concert 
and a tentative, integrated understanding of the clinical implications is proposed.  
 
 
 16                     Introduction                           
                                                
5.3 Acute Coronary Syndromes 
ACS is a unifying term for a set of signs and symptoms reflecting reduced myocardial perfusion 
resulting in myocardial ischemia. If the myocardial ischemia is severe enough to cause 
myocardial cell death, the acute coronary event is classified as an AMI, while ACS without 
evidence of necrosis is called unstable angina. AMI is then further subdivided according to 
whether persistent electrocardiographic ST-segment elevations are present (ST-segment elevation 
MI and non-ST-segment elevation MI). Three variables are at the core of the operational 
definition of AMI: 1) symptoms of ischemia; 2) ECG changes indicative of new ischemia; and 3) 
the detection of a rise and/or fall in biochemical markers of myocardial necrosis (40). In response 
to the continuing diagnostic advances, especially with regard to the measurement of cardiac 
biomarkers, the European Society of Cardiology and the American College of Cardiology 
convened in 1999 to formulate joint recommendations for a Universal Definition of Myocardial 
Infarction (41). The consensus document was updated in 2007 (40).  
  
5.4 Cardiac Troponin in Acute Myocardial Infarction 
5.4.1 The biology of troponin 
Troponin is a protein complex of three subunits (I, C and T) that modulate the calcium-mediated 
interaction between actin and myosin in skeletal and cardiac muscle tissue (figure 1) (42, 43). 
Subunits I and T exist in 3 different isoforms: in fast and slow skeletal muscle and in myocardial 
cells. Each isoform is the product of a separate gene (44-46). The unique myocardial isoforms 
(cTnI and cTnT) can be detected by assays of monoclonal antibodies directed against cardiac-
specific epitopes (47). In the myocardial cells, the majority of the cardiac troponins are bound to 
the contractile apparatus, while a small fraction (3-8 %) is free in the cytoplasm (48-50). In the 
event of myonecrosis, cardiac troponins are released and can be detected in the bloodstream only 
a few hours afterwards, as the cytosolic form is released; and then for a prolonged period of up to 
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2 weeks, as the structural pool is slowly liberated (49, 51). The cardio-specificity coupled with 
the fact that cTnT and cTnI do not circulate in measureable levels among healthy individuals1 has 
given rise to their use in clinical cardiology replacing by and large older markers of myocardial 
injury. Whether cardiac troponin may also be released in response to pure myocyte ischemia 
without necrosis remains controversial (54). 
 
Figure 1. The cardiac troponin subunits and their role in muscle contraction. Adapted from 
Collinson et al (55). 
 
                                                 
1 With the new highly sensitive assays now being developed this is no longer true, as minute amounts of circulating 
troponin are detectable also in a substantial fraction of a healthy reference population (52). Cut-offs and 
consideration of the temporal dynamics of cardiac troponin values are required to differentiate acute events from 
chronic conditions (53). 
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5.4.2 Cardiac troponin assays 
Assays for both cTnI and cTnT have progressively improved since their introduction in the late 
1980s (56-59), and current assays are much more sensitive than previous generations of older 
assays. There are a number of different cTnI assays in clinical use which exhibit a large 
variability in their sensitivities (60, 61). These differences are caused by the extensive 
degradation of cTnI which results in various fragments of circulating cTnI and that antibodies 
used in the different assays detect these fragments differently (62-65). Although cTnT is also 
subject to extensive degradation before and after release from necrotic myocytes (66), 
standardization is not usually a problem as there is only one commercially available cTnT assay, 
although in 5 different generation of assays (52, 57, 67-69). cTnT and cTnI assays provide 
comparable diagnostic and prognostic information, except in patients with renal failure (63, 70).  
 
5.4.3 Current applications in AMI – diagnosis 
Measurement of cardiac troponin is the “gold standard” test for myocardial necrosis and was 
established as the standard serologic biomarker for diagnosis of AMI by the joint committee of 
the European Society of Cardiology/American College of Cardiology in 2000 and in the 2007 
update (40, 41). The cut-off value recommended was at the 99th percentile of a healthy 
population. Compared to the previous biomarker of choice CK-MB, measurement of cardiac 
troponin improves both the specificity and sensitivity for the detection of cardiac injury (71, 72). 
Cardiac troponin is not able to effectively exclude AMI at presentation. Serial measurements are 
necessary and current recommendations advocate a time-interval of at least 6 hours to rule out 
AMI (53). Further improvements of the analytical performance of cardiac troponin assays may 
allow for a slightly earlier diagnosis or rule-out of AMI (73, 74), and adoption of these newer 
assays has been strongly supported by clinical experts (75-77).  
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5.4.4 Current applications in AMI - prognosis 
The prognostic assets of cardiac troponins in non-STEMI were established soon after indications 
of their diagnostic properties emerged (72, 78). A meta-analysis from 2001 of 21 studies 
involving > 18,000 non-STEMI patients found that cardiac troponin elevations were associated 
with a 3.4-fold increase in risk of death and AMI at 30 days (79). The prognostic value of cardiac 
troponin in this setting reflects its correlation with myocardial necrosis. Accordingly, quantitative 
analyses of levels of cardiac troponin – as opposed to a dichotomized categorization of 
positive/negative enhances the predictive value (80). Cardiac troponin release my also be a 
marker of underlying severe coronary stenosis and complex lesions, culprit lesion thrombosis and 
downstream embolization with microinfarction (81-83), although these findings are also linked to 
the total burden of myocardial necrosis.   
In keeping with the mechanistic studies indicating that cardiac troponin elevations signal 
more severe disease, it has been found that cardiac troponin measurements help identify non-ST 
elevation ACS patients who will benefit from various therapeutic interventions. This was initially 
demonstrated for anti-thrombotic treatments such as low-molecular weight heparins and 
glycoprotein IIb/IIIa inhibitors (84-89). It was found that additional antithrombotic therapies 
reduced the risk of adverse events in the cardiac troponin-positive patients, in effect mitigating 
the increased hazard associated with troponin elevations; while no benefit of the drugs was 
observed in troponin-negative patients. Subsequent studies have extended this concept to include 
early coronary intervention (90, 91). 
In STEMI, the prognostic properties of cardiac troponins are influenced by the sampling 
time-point. A positive cardiac troponin on admission is probably reflective of longer ischemic 
time and more extensive myocardial necrosis, and consequently predictive of clinical outcomes 
(92-96). Cardiac troponin levels following reperfusion therapy reflect the extent of myocardial 
necrosis which is the subject of the next section.  
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5.5 Estimation of Infarct Size by Biochemical Markers 
5.5.1 Historical perspective – the initial rationale behind infarct size estimation 
As the establishment of coronary care units in the 1960s reduced mortality from ventricular 
arrhythmias, most deaths following AMI were related to cardiogenic shock and progressive heart 
failure due to extensive myocardial damage (97). At the same time emerging experimental 
evidence suggested that the evolution of AMI was a dynamic process susceptible to mitigation by 
therapeutic interventions (98, 99). Thus, the initial attempts at estimating infarct size by use of 
biochemical markers arose from the need to define surrogate parameters to evaluate experimental 
and clinical trials aimed at cardioprotection and infarct size reduction2.  
 
5.5.2 Historical perspective – the basic principles of enzymatic indices of infarct size 
Elevations of transaminases in peripheral blood in patients with a very recent MI was described 
for the first time by Karmen and Wroblewski in 1954 (101), and the diagnostic utility of 
determination of serum enzyme levels in patients suspected of an acute coronary event was 
established in several studies published in the early 1960s (102, 103). Historically, the three 
enzymatic markers mainly used for infarct size estimation have been CK, its more cardiospecific 
isoenzyme CK-MB, and LDH (also known as alpha-hydroxybyturate dehydrogenase). CK and 
CK-MB are present in the cytoplasm of myocardial muscle cells and the release kinetics are 
characterized by an early peak (< 24 hours) and a rapid return to normal levels (< 72 hours) 
(104). LDH peaks later ( ~ 36 hours) and remains elevated for a much longer time ( > 100 hours) 
(104).  
                                                 
2 The spirit of those times has been vividly captured by one of the early pioneers of that era, Robert Roberts, in the following 
citation: Infarct size was central to the major thrust of cardiac research in the 1970s and as such occupied center stage as the 
culprit to be conquered by interventions designed to cardioprotect and limit myocardial damage (infarct size). Myocardial 
infarction, with its consequent necrosis, was the leading cause of death and came under intense attack with infarct size posing as 
the surrogate villain. Investigators were unified in their attack on infarct size, namely, that its course must be charted, the extent 
of damage quantified, and ultimately therapy designed for its elimination (100).  
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Quantitative models for the estimation of infarct size derived from measuring biochemical 
markers in the systemic circulation were introduced by two different research groups in the early 
1970s (Witteveen and Sobel/Shell) (105, 106). In short, these models aimed to account for the 
cumulative release of the biomarker in question and then relate this directly to the amount of 
necrotic myocardium3. The model by Sobel/Shell was designed on the basis of rigorously 
designed experimental studies of CK and then later for CK-MB (106-110). The Witteveen 
algorithm was a two-compartment model and could be applied for multiple enzymes, but has 
mostly been used with measurement of LDH (104, 105). In the absence of confirmation from 
pathologically determined infarct size, surrogate measures related to cardiac function, 
electrocardiographic findings or clinical outcomes were used to validate the enzyme 
measurements. Critics of both the Sobel and the Witteveen approach claimed that the models 
were sensitive to changes in the underlying assumptions and that the estimates were only useful 
for small infarctions (111-113). Nevertheless, a multicenter, randomized study in which enzyme 
release was correlated directly to quantitative histological measurements of infarct size in 
patients who died, seemed to confirm the accuracy of the enzymatic models (114). 
 
5.5.3  Historical perspective – the influence of reperfusion 
The emergence of reperfusion therapy introduced a new source of uncertainty for enzyme-based 
infarct size estimation as it was found that early recanalization of an infarct-related artery 
accelerated enzyme release. This was initially documented in experimental animal studies and 
then confirmed in clinical trials (115-117). The difference in the kinetics of enzyme liberation 
was not a problem per se, but it was uncertain whether the more rapid rise in enzyme levels also 
                                                 
3 The following parameters were needed: 1) The release ratio, which is the fraction of the marker depleted from the myocardium 
that is released into the circulation; 2) The clearance rate and distribution volume. This was needed to calculate the total amount 
of enzyme released into the blood; 3) The amount (activity or concentration) of the marker that represented a given weight of 
infarcted tissue, so that the size of the infarct could be calculated. This has conventionally been expressed as gram-equivalents. 4) 
Last, the sampling interval necessary to determine a time activity (or concentration) curve so that the total amount released could 
be calculated accurately. 
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signaled a larger total release of enzymes caused by an increased release ratio. If this was the 
case then possibly the cardioprotective potential of reperfusion therapy would not be captured by 
enzyme based infarct size estimation. Although no definite consensus was established, several 
studies found that myocardial LDH release was consistent regardless of whether thrombolytic 
therapy was administered or not (118, 119). Results of much later investigations have since 
supported the validity also of measuring CK AUC or CK-MB AUC for comparison of different 
reperfusion regimens (120). In the 1980s, enzymatic estimates of infarct size were used in several 
trials assessing new treatment regimens (118, 121-123). Some studies used the Witteveen model 
(118, 122) to calculate the total enzyme release and others used the integrated AUC as a 
surrogate for infarct size without calculating the total amount released (121, 123).  
 
5.6 Cardiac troponin for infarct size estimation 
5.6.1 Pathophysiological principles and methodological approach 
The release kinetics of the cardiac troponins in the context of myocardial necrosis are 
characterized by an initial cytosolic liberation with a peak in the case of reperfusion, and then a 
slowly abating plateau phase reflecting degradation of the structural pool (56-59). This makes the 
marker uniquely suited to both early diagnosis of infarction and also, at a later time point, for 
assessing the extent of the myocardial necrosis (49).  
In the absence of reperfusion the release pattern is characterized by a slow increase in plasma 
concentration which peaks at day 3 or 4 (49, 124). Reperfusion therapy induces an early peak of 
both markers as the cytosolic pool is rapidly washed out, but there is no evidence that cumulative 
troponin release is impacted by reperfusion therapy (49, 124, 125). Evidence suggests that 
plasma levels are independent of reperfusion status from the first day and forward, largely 
reflecting the slow degradation and liberation of the structural pool (49, 124). In reperfused 
patients it has been shown that while both cTnT and cTnI peak early (< 12 hours), the 
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disappearance of cTnI is somewhat accelerated compared to cTnT, although both are still 
significantly elevated at 72 hours (126, 127).  
 Most studies on cardiac troponin differ from previous investigations on LDH, CK and CK-
MB in that they do not employ mathematical models to account for the cumulative release of the 
biomarker from necrotic tissue. Several explanations for this simplification exist: First, the 
kinetics and release ratios of the troponins are not very well defined (128). Second, the fact that 
troponins can remain elevated for several weeks makes it impractical to account for the total 
amount released from the myocardium. Last, with the emergence of SPECT and CMR it is 
possible to directly relate cardiac troponin values at specific time points, or as derived variables 
such as peak or AUC, to infarct size determinations from cardiac imaging.  
 
5.6.2 The empirical evidence 
In assessing the subsequent studies on the association between cardiac troponin and infarct size 
and other measures such as LVEF, it is important to recognize the differences in design. The 
most important variables to consider are: 1) the population studied:  STEMI vs. non-STEMI, 
whether reperfusion was given, and the reperfusion modality; 2) which standard was used for 
comparison:  infarct size determined by SPECT, CMR, or other biomarkers, and at what time 
was this examination performed; 3) the cardiac troponin assay employed; 4) the time-points used 
for sampling; and 5), which variables were used in the correlation analyses: peak troponin, AUC 
troponin or at a specified time-point.  
The first report describing the correlation between cardiac troponin and infarct size was 
presented by Hugo Katus and colleagues at a congress in 19914, and the first articles detailing the 
relationship between cardiac troponin and infarct size was published in 1993 (129, 130). Table 1 
                                                 
4 Katus HA et al: Serum troponin T levels on day 4 after acute myocardial infarction are correlated with infarct size. 
9th European Congress of Clinical Chemistry, Cracow, Poland, September 8 – 14, 1991 
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summarizes the published articles reporting correlations between infarct size and cardiac 
troponin.
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5.6.3 Data on cardiac troponin for infarct size estimation and prognostic assessment – the 
situation in 2008 
In total, 18 studies had been performed until the middle of 2008 that investigated the relation of 
cardiac troponin and infarct size or cardiac function. As is evident from table 1 they differed 
widely in size and design. For many crucial questions, the empirical evidence was weak or non-
existent:  
Few studies had employed a cTnI assay, and of those, with a few exceptions from the 90s, 
only the Accu-cTnI assay (Beckman-Coulter, US) had been used. The performance of other 
widely used cTnI assays was not known. Only a handful of small investigations had employed 
CMR as the imaging endpoint. CMR has emerged as the preferred imaging assessment of 
infarcted tissue, because of its precision, high spatial resolution, and ability to delineate even 
small infarctions. The correlation between cTnI measured at early time points and infarct size 
was not well defined. Moreover, most studies had measured infarct size in the immediate 
aftermath of the acute event and the association between cardiac troponins and infarct size 
evaluated in the chronic phase was not well understood. 
Several studies had demonstrated the association of cardiac troponins with LV function and 
volumes following MI (134, 137, 138, 140, 144). However, both LV function and volumes 
evaluated in the sub-acute phase are poor indicators of chronic cardiac status because these 
parameters may change over time due to reversible factors like stunning and hibernation and as a 
result of chronic LV remodeling. No study had investigated whether cardiac troponin may 
complement pre-discharge assessment of LV function and volumes for prediction of LV 
remodeling and chronic cardiac status. Such data are of importance to better define the proper 
role of cardiac troponin measurements in risk stratification. 
A third area where more data were needed concerned the association of cardiac troponin with 
MVO. MVO following reperfusion therapy for STEMI reflects persistent compromised perfusion 
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at the tissue-level. In was initially described angiographically in experimental studies (151). In 
clinical settings it can be diagnosed by various angiographic measures (152, 153), contrast 
echocardiography (154), electrocardiography (155), or CMR (156).  MVO is the result of 
complex pathophysiological mechanisms related to ischemia-reperfusion injury and distal 
embolization of atherosclerotic debris (157). Presence of MVO post-MI is a marker of adverse 
LV remodeling and may be associated with poor prognosis independently of infarct size (158, 
159). Data also suggest that MVO diagnosed by CMR is a stronger predictor of LV remodeling 
than MVO identified by other modalities (156). In this perspective it would be of interest to 
understand whether cTnI release in MI also reflects MVO, independent of infarct size. Only one 
study has looked at the relation of MVO and cTnI (142). This study found that cTnI release at 72 
hours after admission was related to MVO, but did not address whether this relation was 
independent of infarct size. 
 This thesis’ papers I, II and III were designed to address these specific questions mentioned in 
the preceding paragraphs. 
 
5.7 ST-segment recovery for evaluation of reperfusion and prognosis 
5.7.1 ST-segment deviation as a marker of ischemia and reperfusion 
An electrocardiogram is the recording (gram) of the electrical activity (electro) generated by the 
cells of the heart (cardio) that reaches the body surface. A.D. Waller recorded the first 
electrocardiogram in 1887 (160) and in 1903 Einthoven invented the first practical 
electrocardiograph. Einthoven received the Nobel Prize for his “discovery of the mechanism of 
the electrocardiogram” in 1924. The ECG remains a pivotal investigational and diagnostic tool 
in cardiology today.  
ST-segment elevations in response to coronary ligation-induced myocardial ischemia were 
shown in dogs by Smith as early as in 1918 (161). Deviations in the ST-segments are the result of 
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an altered transmembrane potential in the ischemic myocardium compared with adjacent regions 
of non-ischemic myocardial cells. In dogs with occluded coronary arteries, the magnitude of ST-
segment elevation correlated with the extent of myocardial necrosis on histological examination 
(99, 162, 163), and myocardial reperfusion induced normalization of ST-segment elevation 
(164). Later, when fibrinolytic treatment was evaluated in clinical trials, the observation of ST-
segment recovery in response to reperfusion was extended to humans (165).  
Evaluation of ST-segment recovery (or resolution) entails quantifying the amount of ST-
segment deviations after reperfusion therapy in one or several leads. Conventionally, this is 
related to the ST-segment deviations at “baseline” that is recorded before intervention, with ST-
segment recovery being expressed in relative terms as percent of ST-segment recovery. 
Throughout the years, numerous measures of ST-segment recovery have been employed, such as 
relative ST-segment elevation (or deviation) resolution in all affected leads, in the worst affected 
leads, or residual ST-segment elevation (or deviation) in all or one leads (166).  
 
5.7.2 ST-segment recovery following reperfusion therapy by thrombolytics or pPCI 
For the last 20 years, assessment of ST-segment recovery after thrombolytic therapy has been 
used in multiple clinical trials and in patient management and has been shown to provide 
information on epicardial reperfusion status, microvascular function and tissue-level reperfusion 
and prognosis (155, 162, 167). Guidelines recommend evaluation of ST-segments after 
thrombolytic therapy to identify patients with failed coronary reperfusion who are candidates for 
rescue PCI (168).  
In STEMI patients treated with pPCI, where most patients are successfully recanalized, ST-
segment recovery is largely reflective of tissue perfusion and microvascular function. Many 
studies have demonstrated that ST-segment recovery remains a powerful prognostic marker in 
pPCI populations (169-172). These investigations, however, were all retrospective, lacked 
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standardized timing of post-PCI ECGs and preceded the routine use of stents, GP IIb/IIIa 
inhibitors and thienopyridines (173). Additionally, the published reports used very different 
methods for quantifying and categorizing ST-segment recovery. To address these shortcomings 
in the empirical evidence, the investigators of the APEX-AMI (Assessment of Pexelizumab in 
Acute Myocardial Infarction) trial, pre-specified an ECG substudy with core lab analysis of 
protocol-specified postprocedural ECGs, to evaluate the relationship between 6 different 
measures of ST-segment recovery and clinical outcomes in about 5000 STEMI patients (173). In 
this study published in 2008, the APEX-AMI investigators reported that a simple ST-segment 
recovery measure of residual elevation in the most affected lead on the post-PCI ECG performed 
at least as well as more complex methods that required comparison of pre- and post-procedural 
ECGs or calculation of summed ST-segment deviation (173). The results reported from the 
APEX-AMI trial replicated the findings of a post hoc study 4 years earlier by McLaughlin et al 
(172). Furthermore, De Luca et al reached essentially the same conclusions in a prospective 
observational study also published in 2008 (174).   
Several studies have investigated the relation between ST-segment recovery and infarct size 
(175-177). Only one study, however, extended from a pure pPCI population, and this article did 
not compare different algorithms of determining ST-segment recovery (177). In the FIRE trial, a 
core laboratory analysis of protocol-specified ECGs obtained before the intervention, 
immediately following and 90 minutes post-procedure had been performed. Thus, it was possible 
to explore the relation of different measures of ST-segment recovery and infarct size as 
determined by CMR in a contemporary STEMI population all receiving pPCI. This thesis’ paper 
IV investigates the relation of infarct size and ST-segment recovery in the FIRE trial.  
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6. AIMS 
This work was performed to develop more insight into the prognostic applications of cTnI 
measurements at 24 and 48 hours after admission and ST-segment recovery for early risk 
stratification of acute STEMI patients receiving pPCI. The specific objectives can be summarized 
as follows: 
1) to characterize the association between single-point measurements of cTnI and infarct 
size determined by CMR at both < 1 week and 4 months after the index event 
2) to determine the prognostic value of cTnI for prediction of LV dysfunction and changes 
in LV function and volumes from < 1 week after the index event to 4 months 
3) to describe the relation between cTnI and MVO determined by CMR 
4) to characterize the association of 3 measures of ST-segment recovery with infarct size 
and LV function 
 
7. METHODS 
7.1 Study design and population 
All the published articles of the present thesis extend from data gathered in the FIRE trial, which 
was designed to evaluate the cardioprotective efﬁcacy of FX06 as an adjunct to pPCI in patients 
with acute STEMI (31, 32).  The study was conducted between October 2006 and March 2008, in 
a randomized, double blind, placebo-controlled fashion.  
Patients with a ﬁrst STEMI from a single culprit lesion and no other serious comorbidities 
undergoing pPCI as indicated per standard of care were included. Additional inclusion criteria 
were presentation within 6 h of onset of symptoms, > 2 mm ST-segment elevation in at least 3 
ECG leads, and a single culprit lesion with TIMI ﬂow grade 0/1 in the infarct-related artery. 
Patients with prolonged ischemic symptoms, cardiogenic shock, peripheral vascular disease, and 
history of kidney (serum creatinine > 250 mol/l) or liver dysfunction were excluded. Eligible 
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patients were randomly assigned to active drug or placebo. FX06 was administered in 2 
intravenous bolus injections of 200 mg each during PCI, the ﬁrst immediately before the 
guidewire passed the occlusion and the second 10 min (± 5 min) later. Concomitant 
therapies were allowed except for thrombolytics and adenosine. Figure 2 outlines the selection of 
patients in the 4 substudies.  
Written informed consent was obtained from all patients and the study was approved by all 
local ethic committees. All patients were followed up clinically for 4 months.  
Figure 2. Flow charts illustrating selection of patients to each substudy. 
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7.2 Cardiac troponin I measurements 
cTnI was protocol-specified to be sampled in all patients at 24 and 48 hours after admission. All 
samples were analyzed in a blinded core laboratory (Spranger Laboratories, Ingolstadt, 
Germany). cTnI was measured on the Abbott AxSym System (Abbott Diagnostics, Abbott Park, 
Illinois, US) using the second-generation AxSYM Troponin-I ADV assay. The analytical 
sensitivity of the assay is 0.02 ng/ml with a 10% coefficient of variation at 0.16 ng/ml, and the 
99th percentile of a reference population is 0.04 ng/ml. 
 
7.3 Electrocardiographic methodologies 
A standard 12-lead ECG was recorded in all patients at randomization (baseline ECG). 
Additional ECGs were obtained immediately after the intervention as clinically feasible and at 90 
minutes after pPCI. The ECGs were analyzed blinded by the core laboratory at Rigshospitalet, 
Copenhagen University Hospital, Copenhagen, Denmark. ST-segment deviation was measured 
manually at the J-point to the nearest 0.5 mm in all leads. The sum ST-segment deviation was 
calculated as follows: for anterior infarction, the sum of the ST-segment elevation in V1 to V6, I, 
and aVL; for nonanterior infarction, the sum of ST-segment elevation in leads II, III, aVF, V5, 
and V6 and ST-segment depression in leads V1 to V4. 
Three methods for calculating and categorizing ST-segment recovery were used: (1) sum ST-
segment deviation resolution (percentage of resolution of sum ST-segment deviation from 
baseline to after pPCI) analyzed in 3 categories (≥70%, ≥30% to <70%, and <30%); (2) single-
lead ST-segment deviation resolution (percentage of resolution comparing the lead with the most 
prominent ST-segment deviation at baseline and after PCI, irrespective of the 
electrocardiographic lead in which ST-segment deviation was measured at baseline) analyzed in 
3 categories (≥70%, ≥30% to <70%, and <30%); and (3) worst-lead residual ST-segment 
deviation  (the absolute magnitude of residual deviation in the most affected lead on the post-PCI 
                                                           34                                                                     Methods 
 
ECG, without reference to the baseline ECG) analyzed in 3 categories (<1 mm, 1 to <2 mm, and 
≥2 mm). An illustration of the calculation of relative ST-segment recovery and residual ST-
segment deviation is shown in figure 3.  
 
Figure 3. The calculation of relative ST-segment recovery and residual ST-segment deviation. 
 
 
7.4 Cardiac magnetic resonance imaging 
The protocol specified for all patients to undergo CMR examination at 5 days (range 5 to 7 days) 
and at 4 months. The CMR examination involved an ECG-triggered acquisition of a stack of 
short-axis slices covering the entire left ventricle from the base to the apex using steady-state, 
free-precession pulse sequence. The imaging parameters were as follows: slice thickness of 8 
mm, no gap between slices, temporal resolution > 50 ms, matrix 224 to 256 x 224 to 256 using 
magnetic resonance scanners from all major vendors operating at 1.5 Tesla. In addition, long-axis 
2-, 3-, and 4-chamber views were acquired with the same parameter settings. Late gadolinium 
enhanced images were acquired in the same slice orientations 20 minutes after administration of 
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a gadolinium-based contrast agent (0.25 mmol/kg). Inversion time was adjusted in each patient to 
null the signal of normal myocardium. The gadolinium enhanced images were obtained in mid to 
late diastole to minimize motion by adjusting the trigger delay (~ 450 ms). Other imaging 
parameters were as follows: slice thickness of 8 mm without gap, matrix 192 to 256 x 192 to 256, 
and ﬂip angle 20°.  
Using short-axis cine loops of the left ventricle from base to apex, endocardial and epicardial 
contours were traced manually in each slice at end systole and end diastole to measure areas. 
LVEF, ESVI and EDVI, and myocardial mass were calculated in a standard fashion. All short-
axis slices were assessed for areas of signal enhancement. Total volumes of signal enhancement 
were obtained by summing compartments of all slices covering the entire left ventricle and 
expressed as a percentage of LV myocardial mass. MVO was defined as any region of 
hypoenhancement within the hyperenhanced area and was included in the calculation of 
total infarct size. 
All images were analyzed at the central site by a single, blinded, experienced CMR reader 
followed by blinded review by a level III CMR expert (Peter Buser or Jens Bremerich, University 
Hospital, Basel, Switzerland). In the case of discordance between the primary and expert 
reviewer, consensus was reached. Intraobserver variability was assessed in a subset of 40 
randomly chosen studies and the intraclass correlation was 0.85 for 26 studies from day 5.  
 
7.5 Statistical methodologies 
The data were approached statistically by a limited set of analyses. Variables are presented as 
mean (standard deviation) or median (interquartile range) depending on the distribution. 
Associations between variables are reported as Pearson correlations or Spearman rank 
correlations. Differences between groups were assessed by Student’s t-test or Wilcoxon rank sum 
(Mann-Whitney U) test depending on the distribution of the variables. Linear regression and
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binary logistic regression models were used to explore relations between variables. For 
multivariable analyses, variables were either entered into the model in block or following 
univariable analysis (with a p-value of 0.2 as the criterion for inclusion). Receiver operator 
characteristics curves and c-statistics were generated to show the ability of cTnI alone or 
prognostic models to discriminate between binary outcomes (i.e. small vs. large infarct size or 
LVEF < 40 % vs. ≥ 40 %).  
8. RESULTS 
8.1 Paper I 
The association between infarct size and single-point sampling of cTnI was investigated. There 
was a highly significant correlation between late gadolinium enhanced CMR measured infarct 
size and cTnI sampled at 24 (r = 0.66 (5 days) and r = 0.63 (4 months)) and 48 hours (r = 0.67 (5 
days) and r = 0.65 (4 months)). In a multiple regression analysis for predicting infarct size at 4 
months (n = 141), cTnI and infarct location retained an independent association with late infarct 
size even taking into account early infarct size. 
 
8.2 Paper II 
The ability of cTnI to provide prognostic information on chronic LV dysfunction and LV 
remodeling following STEMI was explored. In linear regression models adjusted for early 
(5 days) assessment of LVEF, ESVI and EDVI, single-point cTnI at either 24 or 48 h were 
independent and strong predictors of changes in LVEF (p<0.01), EDVI (p<0.01) and ESVI 
(p<0.01) during the follow-up period. In a logistic regression analysis for prediction of an LVEF 
below 40% at 4 months, single-point cTnI significantly improved the prognostic strength of the 
model (AUC = 0.94, p<0.01) in comparison with the combination of clinical variables and LVEF 
at 5 days. 
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8.3 Paper III 
The paper explored the association of cTnI and MVO in STEMI patients receiving pPCI. The 
presence of MVO following STEMI was associated with larger infarct size and higher values of 
cTnI at 24 and 48 h. For any given infarct size or cTnI value, there was a greater risk of MVO 
development in non-anterior infarctions. cTnI was strongly associated with MVO in both anterior 
and non-anterior infarctions (p < 0.01) after adjustment for covariates including infarct size. 
 
8.4 Paper IV 
The paper aimed to define the association between infarct size and cardiac function as 
determined by CMR imaging and different metrics of ST-segment recovery. All 3 ST-segment 
recovery algorithms were associated with the final infarct size and cardiac function. Worst-lead 
residual ST-segment deviation performed the same as, or better than, the more complex methods 
and identified large subgroups at either end of the risk spectrum (median infarct size from the 
lowest to highest risk category (percentage of left ventricle: 7.7% [interquartile range 10.8], 
13.1% [interquartile range 13.6]; 24.6% [interquartile range 21.1]); with adjusted odds ratios for 
infarct size greater than the median (reference <1 mm): 1 to <2 mm, odds ratio 2.3 (95% 
confidence interval 0.8 to 5.9); ≥ 2 mm, odds ratio 6.3 (95% confidence interval 1.7 to 23.7; c-
index 0.781). 
 
9. DISCUSSION 
Our results suggest that both cTnI and the ECG convey significant prognostic information in the 
early phase following pPCI. Swift initial triage and timely reperfusion therapy have significantly 
improved survival for STEMI patients, and the advent of pPCI as compared to fibrinolytic 
therapy has further impacted clinical outcome. Even so, a wide spectrum of risk still exists for 
STEMI patients and effective risk stratification remains important, especially to identify high-
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risk patients. Thus, our findings are of clinical relevance as they suggest that simple and 
accessible markers are available that may facilitate identification of high- and low-risk patients.   
 
9.1 The association of cTnI with infarct size and measures of LV function and volumes 
In paper I we found that a single-point determination of cTnI at 24 or 48 hours after admission 
was associated with infarct size. These results confirm previous studies on the relation of infarct 
size and cTnI in STEMI patients, but also expand current knowledge along a number of 
dimensions:  
First, our report is the largest assessment to date of cTnI or cTnT and their association with 
CMR-determined infarct size. Previous studies were smaller and all measured infarct size < 1 
week after the index event (139, 141-143). In terms of infarct size measured < 1 week, our data 
confirmed the findings of these earlier investigations. Our second assessment of infarct size at 4 
months showed a marked involution of the infarcted area. This is in keeping with other studies 
that have assessed infarct size with CMR or SPECT in a serial fashion (178-180). However, we 
found that this involution did not reduce the strength of the association between cTnI and infarct 
size. Two recent articles also reported strong correlations between cTnT and infarct size at 4 
months in STEMI patients (146, 150). Interestingly, in regression analyses, we demonstrated that 
cTnI was associated with infarct size at 4 months even when adjustments were made for early 
infarct size. This suggests that cTnI early after STEMI captures unique information on the extent 
of irreversible myocardial injury that is complementary to that provided by imaging analysis. 
This finding is in keeping with cardiac troponin being a marker of cardiomyocyte necrosis. 
Second, the present study is only the second to report on cTnI measured with the Abott 
AxSym ADV assay. These data thus validate the assay for infarct size estimation following 
STEMI. After our study was conceived, Stanley Chia and co-workers published their analyses of 
the EVOLVE (The Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI) trial, 
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where the same cTnI assay as we employed was correlated with SPECT determined infarct size 
(126). Their results are in line with our findings, but infarct size was evaluated at 5 and 30 days, 
and not at 4 months as in our study. 
A third novel aspect of our study is that cTnI was determined at 24 and 48 hours. Although 
some studies have performed sampling of cTnT or cTnI at these time-points previously, our 
study is the first to demonstrate the utility of this sampling strategy in a population of STEMI 
patients all receiving pPCI with infarct size estimated at > 3 months. A very recent article 
published in 2011 has replicated these results for cTnT (150). That a single-point value at 24 
hours is comparable to later sampling is consistent with the notion that cTnI values at 24 hours 
and beyond are reflective of the total infarct burden. However, nearly all patients in the FIRE 
trial were successfully reperfused, and extrapolation of these results to populations with a less 
uniform reperfusion status should be done cautiously.  
Paper II showed that cTnI determined at 24 or 48 hours after admission is independently 
associated with chronic LV function and the volumetric changes that take place in the 4 months 
following the index event. This association persisted when adjustments were made for LV 
function and volumes measured before discharge.  
Previous investigations have demonstrated that cTnT and cTnI are associated with LV 
function following MI (134, 137, 138, 140, 144). Only one of these analyses was based on a 
pPCI population and this investigation determined LVEF at 30 days by SPECT (144). Our study 
replicates these results with a second-generation cTnI assay and with LVEF measured at both < 1 
week of the index-event and at 4 months. With the same cTnI assay, Chia et al have recently 
published results in agreement with our data in a comparable population (126). Our data thus 
confirms previous findings. The novel aspect of the present study is the analysis of the 
association of cTnI with the time-dependent changes of LV function and volumes. 
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Our data confirm that in patients treated with pPCI substantial improvements in LVEF can 
occur throughout the first months after the acute event (179, 181-184). The principle mechanisms 
by which improvement in function occurs are thought to be myocardial salvage, stunning and 
hibernation (184-186). Given the 5-7 day delay in LVEF measurement following the acute event 
in our population, it is likely that recovery from myocardial stunning and possibly hibernation 
were the main underlying factors responsible for the marked improvement of LV function 
observed in a subset of patients. Our data are also consistent with clinical and experimental 
evidence showing that infarct size is the major determinant of LV remodeling and chronic LV 
function (179, 180, 182, 187-189). To our knowledge, our study is the first to demonstrate that 
cTnI, as a surrogate for infarct size, is associated with changes in LV function and volumes, and 
gives incremental prognostic information on chronic cardiac status to that provided by 
assessment of LVEF and LV volumes pre-discharge. The major determinants of long-term 
clinical outcome in both the pre- and post-reperfusion therapy era are chronic LVEF and end-
diastolic and end-systolic volumes (190, 191). Thus, our findings strongly suggest that a single-
point cardiac troponin value following STEMI may also be associated with clinical outcomes in 
the long-term. This hypothesis has been investigated in a small prospective study and the results 
appear to support this notion (192).  
Some tentative clinical implications are suggested by these data with the caveat that this is a 
post hoc analysis. The findings indicate that a single cTnI determination after STEMI is 
instructive for early assessment of risk despite echocardiographic assessment of function and 
volumes before discharge. In particular, in patients with an initial LVEF < 40 %, it is likely that 
cTnI sampling would facilitate identification of a high-risk population with poor prospects for 
recovery of function, that could be targeted with aggressive and comprehensive anti-remodeling 
strategies. Likewise, for design of clinical trials aimed at improving post-MI outcomes, cTnI may 
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be an attractive candidate for logistically simple and reasonably accurate identification of high-
risk populations that will benefit the most from novel interventions.  
 
9.2 Microvascular obstruction and cTnI 
We found cTnI at 24 or 48 hours following pPCI to be associated with the presence of MVO 
determined by CMR, independent of early infarct size.  
More data has recently been published on the importance of MVO for development of 
adverse LV remodeling and dysfunction following STEMI (180, 193, 194). In agreement with 
our results, Neizel et al recently found that cTnT 24 hours after admission was independently 
associated with presence of MVO adjusted for infarct size (195).  
 Several interesting results emerged from our analyses. First, the independent association 
between MVO and cardiac troponins suggested by other investigations is confirmed (180, 195). 
This is important as it indicates that levels of cardiac troponin in the context of MI are not only 
reflective of the extent of the initial infarction, but also with presence of MVO. As such, these 
results help explain and are entirely consistent with the ability of cTnI to predict adverse LV 
remodeling and dysfunction as demonstrated in paper II.  
Second, we observed that the propensity for MVO development, in terms of infarct size or 
cTnI, is dependent on infarct location. This finding argues that the strong association between 
larger infarct size and presence of MVO reported in multiple studies is not causal, but rather a 
result of confounding. In fact, other investigations have also found that the likelihood of MVO 
development is similar between infarct locations (195, 196).  Taken together, the results of paper 
III reinforce the concept of cTnI as an important risk stratification tool after STEMI, although the 
direct clinical relevance of these specific findings has yet to be defined. 
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9.3 ST-segment recovery and infarct size and cardiac function 
Our study demonstrated that ST-segment recovery following pPCI for STEMI is associated with 
chronic infarct size and cardiac function. Furthermore, we found that among the three different 
metrics of ST-segment recovery we tested, the simple measure of absolute ST-segment deviation 
in the worst lead at 90 minutes compares favorably with the more complex algorithms of relative 
ST-segment recovery. The worst-lead residual measure of ST-segment recovery defined a wide 
spectrum of risk and identified both a high-risk population (infarct size > 24 % of LV) and a 
large low-risk group (infarct size < 8 % of LV). These results are completely consistent with data 
on clinical endpoints from the comparable population enrolled in the APEX-AMI trial. 
Interestingly, the proportion of patients allocated to each risk category closely mirrored that 
found in APEX-AMI (173).  Our study highlights the probable link (i.e. infarct size) between ST-
segment recovery and clinical outcome observed in APEX-AMI.  
 The present data were the first to link chronic infarct size estimated by CMR with the simple 
measure of worst-lead residual ST-segment deviation. Since our results were published, several 
studies have emerged that correlate ST-segment recovery with infarct size determined by CMR 
(197-199). Two of these studies confirm the association of ST-segment recovery with infarct 
size, but did not include analysis of the worst lead residual ST-segment deviation (197, 198). The 
third recent study also included residual ST-segment elevation, but applied the more complex 
method of summing all ST-segment elevations together (199). They found an association 
between summed residual ST-segment elevation and LVEF but not infarct size, when controlling 
for infarct location and number of Q-waves. These findings have yet to be replicated in other 
populations and methodological concerns with this study have also been expressed regarding 
selection of the patient population and estimation of infarct size (200).  
More data have recently emerged on ST-segment recovery and clinical outcome at 1 and 5 
years (201, 202). These studies did not extend from randomized trials but looked at all-comer 
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STEMI patients receiving pPCI at one center in Holland. The findings suggest that the prognostic 
power of ST-segment recovery is not restricted to patients enrolled in clinical trials. 
The reason why the simple measure of post-PCI residual ST-segment deviation performs 
equal to, or better than, the more elaborate assessment strategies is not entirely clear; however, 
the relative measures may be prone to some imprecision owing to their heavy dependence on the 
preprocedural level of ST-segment deviation. The timing of the post-PCI ECG may also 
influence results. Across all 3 ST-segment recovery metrics studied, we found that the 
correlations with infarct size and LVEF were stronger at 90 minutes than immediately following 
the procedure. Other reports have observed the opposite trend (203, 204). The methodological 
approach of one of these studies has recently been questioned, however (204, 205). A recent 
analysis found no difference between early assessment and at 90 minutes (206). In APEX-AMI 
ECGs were analyzed at 30 minutes and these results appeared very similar to ours. Therefore, 
analysis of ST-segment recovery in a time-window of 30 and 90 minutes post-PCI seems 
appropriate.  
Considered in the context of the cumulative evidence that our findings support, it is 
reasonable to draw some tentative clinical inferences from them, although confirmation from 
prospective studies are needed. It seems clear that analysis of worst-lead residual ST-segment 
deviation between 30 and 90 minutes following pPCI represents an extremely simple way of 
identifying high-risk patients. No randomized trials have been conducted to study whether 
specific interventions are of benefit in the acute phase to mitigate myocardial damage or 
complications in this high-risk population. Notwithstanding, close monitoring and early initiation 
and quick up-titration of therapies with well-established cardioprotective properties like renin-
angiotensin system inhibitors and beta-blockers seem appropriate. 
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9.4 Discussion of the methodological approaches 
9.4.1 Substudies of randomized trials - strengths and limitations 
The present thesis is based on a database from a randomized trial. Randomized trials often 
provide researchers with unique opportunities to develop further insight into the study population 
beyond addressing the primary research hypothesis. Indeed, it has recently been argued that 
investigators have an ethical and financial responsibility to design and conduct trials in a fashion 
that maximizes the scientific knowledge (207). Contemporary, international and carefully 
monitored randomized trials generate a well-validated database. All of the studies included in this 
thesis are robust in the sense that the data points were prospectively defined and registered by an 
independent clinical research organization.  
However, it is also important to recognize the potential pitfalls of performing substudies 
based on clinical trials. Often randomized trials have strict inclusion criteria which may limit the 
external validity of the results, thus restricting the ability of such investigations to inform clinical 
practice. The FIRE population obviously represented a select cohort of patients. Patients in 
cardiogenic shock, with serious comorbidities, or prior MI were excluded. Moreover, inclusion 
criteria for ST-segment elevations were more stringent than defined in the guidelines, requiring 
ST-segment elevation > 2 mm in at least 3 leads. Thus, extrapolation of the results to different or 
more complex clinical scenarios should only be performed with caution. 
The present thesis considered the trial population in FIRE combined. Although the trial 
overall was negative and adjustments were made for randomization in several of the analyses, we 
cannot totally rule out the possibility that some of the variables we studied were affected by the 
study drug intervention. 
Another point to consider is the “fooled by randomness” effect (208), where spurious, 
random relationships mistakenly are interpreted as being real. Post hoc analyses increase the 
probability of such false “discoveries”. Certainly, this possibility cannot be excluded, but the 
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results of this thesis, while novel, fit very well with previous analyses. Moreover, the findings are 
biologically plausible and consistent with mechanistic insights. Nevertheless, it is clear that our 
findings have to be validated in prospective trials, preferably designed to also account for clinical 
endpoints.  
 
9.4.2 Sampling of cTnI 
Several issues should be considered. Clearly, it would have been preferable with more sampling 
time points for comparative purposes. Yet, evidence suggest that there are no large differences 
between sampling at 24, 48, 72 or 96 hours (145), and our findings are in line with correlation 
coefficients reported at 72 hours with the same assay (126). In any case, our results demonstrate 
the clinical utility of an early sample and how it may be integrated with other prognostic 
variables like LVEF. 
Given the multicenter design of the trial and the decentralized collection of samples, some 
variability in the cTnI measurements would be expected, both in terms of the timing of blood 
drawing and in pre-analytical conditions (the specimen integrity). Such variability, by increasing 
the background “noise” level in the data, would weaken the associations with the various 
outcome measures as reported here. On the other hand, our findings extend from a population 
where nearly all patients presented within 6 hours from onset of symptoms and had successful 
pPCI which probably resulted into a more uniform cTnI release pattern than what can reasonably 
be expected in a real-world setting.   
For application of these results in clinical practice, a major drawback is the lack of 
standardization across cTnI assays (61). Even for the specific assay reported on here, clinical 
application of the findings would be contingent on knowing roughly what any given cTnI value 
corresponds to with respect to infarct size or cardiac function, and specific values reported here 
should be validated in a prospectively designed study. 
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9.4.3 Electrocardiogram 
ECG analyses were performed by an independent core laboratory blinded to patient data and 
study outcomes. ST-segment deviation was measured at the J-point. There is no consensus 
regarding the exact position along the ST-segment that should be selected for measurement and 
various studies have employed different positions. In STEMI, the deviated ST-segment may be 
horizontal, downsloping, or upsloping. Thus, the precise impact of different measuring points 
would be dependent on ST-segment configuration in each individual patient. However, for 
internal validity, consistency in selection of the measurement point is paramount. As already 
mentioned, the timing of the post-PCI ST-segment analysis should also be considered when 
comparing different studies. In relation to this point, and given the dynamic evolution of ST-
segment deviations, it is unquestionable that continuous ST-segment monitoring following 
reperfusion therapy would have provided additional and more sophisticated information than a 
snapshot at 90 minutes.  
 For calculation of ST-segment recovery we also included ST-segment depression in order to 
account for reciprocal ST-segment elevations. This may potentially complicate comparison with 
studies only measuring ST-segment elevation, although this impact is likely to be minor.  
 
9.4.4 Cardiac magnetic resonance 
In the setting of an AMI, CMR can provide a wide range of information, such as infarct size, 
MVO detection, myocardial edema (area at risk) and also allows for a highly reproducible 
assessment of cardiac function and volumes (209). It represents a powerful tool for a global 
evaluation of post-infarction remodeling. However, there are still significant challenges in terms 
of reproducibility among different laboratories particularly concerning the use of contrast-
enhanced CMR for estimation of infarct size (200, 210). Thus, interpretation of our results should 
                                                           47                                                                 Discussion 
 
be considered in the context of these remaining challenges and the infarct size measurements 
found in the FIRE trial may not be directly compared with other reports. 
CMR images were analyzed by an experienced imaging core laboratory blinded to patient 
data and study outcomes. The multicenter and international design of the trial entailed that 
images were obtained in multiple sites with varying experience with CMR. The quality of image 
acquisition in each site was evaluated before the study was initiated and found to be acceptable at 
all participating sites. Despite this, not all images were of optimal quality. On the other hand, 
thorough and careful analyses by the core laboratory ensured a common standard for 
interpretation and a low intersubject variability. Because of the multiple sites involved, the CMR 
protocol specified a somewhat larger dose of gadolinium (0.25 mmol/kg) than is conventionally 
used for the late-enhanced images, as it has been shown that increasing doses (up to 0.3 
mmol/kg) improve sensitivity for detection of myocardial injury (211). Late-enhanced images 
were protocol-specified to be obtained at 20 minutes after contrast-injection. Estimation of 
infarct size between 10 to 30 minutes after contrast is highly reproducible (212).  The area of the 
infarction was delineated manually. There is presently no accepted standardized quantitative 
method for measurement of infarct size (213), although automated or semi-automated approaches 
have been proposed (214, 215).  
 Visualization of MVO is highly dependent upon the mode and timing of CMR assessment 
(216). In the FIRE trial, CMR examination were performed during an interval (5 to 7 days) where 
earlier studies have suggested that presence and extent of MVO is fairly constant (217). Both 
first-pass perfusion and late-enhanced imaging can be used to characterize MVO by CMR (216). 
First-pass perfusion is the most sensitive technique, while late-enhanced imaging detects fewer 
patients with a worse functional outcome (156). It is not known which modality is the strongest 
prognosticator, as recent studies have reached opposite conclusions (156, 180, 194). In our study, 
due to the timing of image acquisition, some areas of MVO may have disappeared because of 
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contrast wash-in from surrounding regions. If so, this would further have exacerbated a selection 
bias in favor of more severe MVO. Thus, characterization of MVO by first-pass perfusion would 
have identified more MVO patients and results may have been different.  
 
9.4.5 Statistical methodologies 
The statistics applied in these analyses were based on conventional methods. Associations 
between variables were mostly assessed by Pearson correlations. For continuous data, Pearson 
correlations are appropriate as long as the relation between the variables is linear, irrespective of 
whether they are normally distributed or not (218). For the linear regression analyses, the 
assumption of normally distributed residuals (i.e. difference/distance between observed and 
predicted values) was met. Another assumption of linear regression is that the variance of the 
error terms is constant, or in other words that the imprecision of the predicted values of Y is 
constant for all observed X-values (homoscedasticity). In the linear regression analysis with cTnI 
(independent variable) and infarct size (dependent variable) the model indicated that the 
prediction of infarct size is more imprecise for larger infarctions compared to smaller infarction 
(in other words evidence of heteroscedasticity). Not unexpectedly, a casual inspection of the 
scatter plots of other reports on cardiac troponins and infarct size suggests that this is not 
restricted to our data (143, 146, 149).  Heteroscedasticity will not bias the relationship between 
the dependent and independent variables, but may impact the standard errors. We found no 
evidence of other assumptions not being met in the regression analyses. It should be commented 
that for estimation of infarct size, since we did not apply forced fits through (x,y) = (0,0), there 
will be some overestimation of small infarctions at low cTnI levels.  
 Inclusion in each individual substudy was based on whether the variables under investigations 
had been collected or not. Thus, in paper I, II and IV patients who did not return for a repeat 
CMR examiniation at 4 months were exlcuded (also if cTnI samples were missing). As reported 
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in paper I and IV, baseline characteristics of the study populations were representative of the 
whole FIRE population. Bias may have been introduced, though, if there was a systematic 
difference between those patients who completed follow-up and those who did not. Even if a 
significant, systematic bias was present, it is not clear how that would impact the assocations 
between cTnI or ST-segment recovery and infarct size/LV function, but this possibility cannot be 
discounted. There was some inconsistency in selection of patients for each substudy with regards 
to the criterion for cTnI samples. In paper I, patients with missing cTnI at 48 hours were 
excluded, while in paper II patients with missing values at either cTnI at 24 or 48 hours were 
excluded, and finally in paper III, patients with missing cTnI at 24 hours were excluded. This 
lack of uniformity is unfortunate. 
 
9.5 The relation of our findings with clinical risk scores and other prognostic tools 
Our results should also be considered in the context of the many existing risk scores that have 
been proposed for AMI patients. In a comprehensive review of post-MI risk stratification in the 
reperfusion era, Michaels and Goldschlager identified no less than 42 variables independently 
associated with clinical outcomes (219). Various constellations of these variables have been 
combined in many different risk indexes over the years. A recent review evaluated the ability of 
5 scoring systems based on information available at first medical contact to define high-risk 
patients for an endpoint of 30 day mortality in STEMI patients treated with pPCI (220). They 
found a large heterogeneity in the prognostic properties of the various models. Excluded in this 
analysis were studies also incorporating angiographic variables as evaluated by Halkin et al (221) 
and De Luca et al (222) in two large datasets of pPCI populations, as well as a recent study 
extending from the APEX-AMI trial (223). Expectedly, many of the variables found to be 
predictive of mortality are common among many of the studies like age, Kilip class, anterior MI 
and renal insufficiency.  
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The usefulness of prognostic information is a product of the time at which the information is 
available and the precision. Clinical risk scores based on information at admission or during 
acute intervention are imprecise but nonetheless extremely valuable because the early time-point 
allows for a broad range of therapeutic responses. As indicated by our analyses, both single-point 
cardiac troponin measurements and indexes of ST-segment recovery add incremental prognostic 
information to clinical and procedural variables. However, the therapeutic options in response to 
this information are more limited due to the delayed time at which it is available. Nevertheless, 
information at 90 minutes post-PCI and then at 24 hours, may still be highly instructive for 
clinical decision-making regarding monitoring, adjunctive medical therapy and decisions on 
discharge and follow-up. As such, clinical and procedural risk scores, ST-segment recovery, 
measurement of cardiac troponin and evaluation of LV function before discharge may all play 
complementary roles in prognostic assessment of STEMI patients. 
 
9.6 An integrated view of our findings 
The concerted application of measures of ST-segment recovery and cTnI for risk stratification in 
a clinically plausible scenario could look like this (figure 4): Following pPCI, an ECG is obtained 
at 30 – 90 minutes after the intervention. In this assessment, patients with a residual ST-segment 
elevation ≥ 2 mm in the worst lead constitute a high-risk population who are likely to develop 
large infarctions with substantial chronic LV dysfunction.  Thus, one could speculate that these 
patients may benefit from careful monitoring and more aggressive pharmacological strategies 
already at this early stage. At 24 hours, sampling of cTnI should be performed for further risk 
stratification. A low value (reference values would need to be defined) would indicate successful 
reperfusion therapy and little irreversible myocardial injury with a favorable short- and long-term 
prognosis. A subsequent echocardiographic assessment should be interpreted in light of the cTnI 
value. For example: A low cTnI value in the context of a severely impaired LVEF suggests a 
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large potential for recovery of function in the subsequent weeks following discharge. On the 
other hand, a low LVEF concomitant with a high cTnI value signals a poor prognosis and 
increased risk of adverse events. These patients in particular may benefit from an aggressive anti-
remodeling strategy with renin-angiotensin inhibitors and possibly aldosterone antagonists and 
close follow-up (22, 39). 
Figure 4. Diagrammatic, tentative illustration of different stages in risk stratification of STEMI 
patients 
 
 
10. CONCLUSION 
The aim of the present thesis was to generate further insight into the prognostic role of the cTnI – 
a marker of myocardial necrosis – and the ECG in patients with STEMI receiving pPCI.  
1) In paper I we showed that cTnI measured at a single time-point following pPCI (24 or 48 
hours) is associated with early and late infarct size.  
2) In paper II we found that cTnI complements other conventional risk stratification tools before 
discharge in prediction of LV remodeling and chronic LV function.  
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3) In paper III we demonstrated that cTnI is associated with MVO determined by CMR and that 
this association is independent of initial infarct size.  
4) In paper IV, our analyses showed that ST-segment recovery is associated with final infarct 
size and LV function and that a very simple algorithm requiring only the post-pPCI ECG is at 
least comparable to more complex methods for risk stratification.  
The clinical utility of these results for prognostic assessment of AMI patients awaits further 
prospective studies. 
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